The RNA therapies market is experiencing explosive growth, driven by advancements in mRNA, siRNA, and antisense oligonucleotide therapies. Over 80 companies are actively developing 100+ RNA therapies across various stages, targeting diseases like cancer, infectious diseases, and genetic disorders. DelveInsight’s report, ‘RNA Therapies Competitive Landscape – 2024’, provides a comprehensive analysis of this dynamic market, highlighting key players, pipeline drugs, and future growth potential.